Literature DB >> 1855775

Is exocrine pancreatic cancer a hormone-dependent tumor? A study of the existence of sex hormone receptors in normal and neoplastic pancreas.

E M Targarona1, M D Pons, G Gonzalez, L Boix, V Marco, C Marco.   

Abstract

The 5-year survival rate of patients with exocrine pancreatic cancer after surgery is less than 5%, in patients treated with radical surgery, with or without adjuvant therapy. It has been well documented clinically and experimentally that sex hormones influence the physiology of the exocrine pancreas. Hormone manipulation inhibits the growth of human pancreatic cancer in nude mice. Several nonrandomized studies have suggested the efficacy of antihormone therapy in the treatment of advanced pancreatic cancer. However, the existence of sex hormone receptors in exocrine pancreatic cancer has been a matter of controversy. This study was designed to investigate the presence of sex hormone receptors (estrogens, progesterone and androgens in normal pancreas and exocrine pancreatic cancer, using two different methods: immunohistochemistry and enzyme immunoassay. Twenty-eight biopsies of normal pancreas and 15 biopsies of exocrine pancreatic cancer were studied. Estrogen receptors and progesterone receptors were measured by enzyme immunoassay, using specific monoclonal antibodies. Androgen receptors were determined by radioligand assay. Sixteen biopsies of normal pancreas and 12 biopsies of exocrine pancreatic cancer were studied by immunohistochemistry. In exocrine pancreatic cancer we could not detect estrogen receptors or progesterone receptors, either by enzyme immunoassay or immunohistochemistry. Androgen receptors were always negative (less than 2 fm/mg). In the normal pancreas, 5 out of 28 cases showed increased levels of progesterone receptors (greater than 10 fm/mg) as measured by enzyme immunoassay. Immunohistochemistry revealed progesterone receptors in the pancreatic islets of 16 normal pancreases studied. Nuclear staining was observed in more than 70% of the cells. Estrogen receptors were always negative by immunohistochemistry and enzyme immunoassay in the normal pancreas.2+n

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1855775

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  4 in total

1.  Cytosolic estrogen and progesterone receptors in exocrine pancreatic adenocarcinoma.

Authors:  C Mao; D Desaty; J M Howard
Journal:  Int J Pancreatol       Date:  1994-04

2.  Flutamide in unresectable pancreatic adenocarcinoma: a randomized, double-blind, placebo-controlled trial.

Authors:  Sanjay Singh Negi; Anil Agarwal; Adarsh Chaudhary
Journal:  Invest New Drugs       Date:  2006-05       Impact factor: 3.651

3.  Mucinous cystadenocarcinoma of the pancreas diagnosed in postpartum.

Authors:  Rene Berindoague; Eduard Targarona; Alfredo Savelli; Juan Pernas; Josep Lloreta
Journal:  Langenbecks Arch Surg       Date:  2007-05-26       Impact factor: 2.895

4.  Expression of estrogen receptors during growth of human pancreatic adenocarcinoma cells (Capan-1)-relationship with differentiation.

Authors:  E Hollande; M Fanjul; N Houti; J C Faye; P Courriere
Journal:  In Vitro Cell Dev Biol Anim       Date:  1998 Jul-Aug       Impact factor: 2.723

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.